Quality-of-life questionnaire for patients taking antihypertensive medication

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1771-1787

  Nelsen, Linda M ^a   Himmelberger, David U ^b   Morrison, Alan ^a   Berger, Marc L ^a   Markson, Leona E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Health Outcomes Group   (United States)

Author keywords

Antihypertensive agents; Health related quality of life; Hypertension; Merit Reduction Method; Questionnaires; Respondent burden

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LETHARGY; MALE; NAUSEA; NOCTURIA; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SYMPTOM; VERTIGO; VISUAL IMPAIRMENT;

EID: 0032746120     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80055-1     Document Type: Article

References (49)

1. 1. Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. Br Med J. 1995;311:293-295.
2. 2. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
3. 3. Curb JD, Borhani NO, Blaszkowski TP, et al. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253:3263-3268.
4. 4. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension: Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981;2:539-543.
5. 5. Solomon S, Hotchkiss E, Saravay SM, et al. Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry. 1983;40:1109-1112.
6. 6. Hunt SM. Quality of life claims in trials of anti-hypertensive therapy. Qual Life Res. 1997:6:185-191.
7. 7. Hjemdahl P, Wiklund IK. Quality of life on antihypertensive drug therapy: Scientific end-point or marketing exercise? J Hypertens. 1992;10:1437-1446. Editorial.
8. 8. Haynes RB, Sackett DL, Taylor DW, et al. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med. 1978;299:741-744.
9. 9. Hollenberg NK, Testa M, Williams GH. Quality of life as a therapeutic end-point: An analysis of therapeutic trials in hypertension. Drug Saf. 1991;6:83-93.
10. 10. Os I. Quality of life in hypertension. J Hum Hypertens. 1994;8(Suppl 1):S27-S30.
11. 11. Levine S, Croog SH. What constitutes quality of life? A conceptualization of the dimensions of life quality in healthy populations and patients with cardiovascular disease. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing Inc; 1984:46-58.
12. 12. Gandhi SK, Kong SX. Quality-of-life measures in the evaluation of antihypertensive drug therapy: Reliability, validity, and quality-of-life domains. Clin Ther. 1996;18:1276-1295.
13. 13. Bulpitt CJ, Fletcher AE. Quality-of-life instruments in hypertension. Pharmacoeconomics. 1994;6:523-535.
14. 14. Wiklund IK. Hypertension. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996:893-902.
15. 15. Beto JA, Bansal VK. Quality of life in treatment of hypertension: A metaanalysis of clinical trials. Am J Hypertens. 1992; 5:125-133.
16. 16. Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther. 1996;18:608-625.
17. 17. Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther. 1996; 18:411-428.
18. 18. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997;17:140-147.
19. 19. Kusek JW, Lee JY, Smith DE, et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17(Suppl 4):40S-46S.
20. 20. Lawrence WF, Fryback DC, Martin PA, et al. Health status and hypertension: A population-based study. J Clin Epidemiol. 1996;49:1239-1245.
21. 21. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): IL Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31: 247-263.
22. 22. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
23. 23. Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med. 1991; 151:1817-1823.
24. 24. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing Inc; 1984:170-183.
25. 25. Fletcher AE, Bulpitt CJ, Chase DM, et al. Quality of life with three antihypertensive treatments: Cilazapril, atenolol, nifedipine. Hypertension. 1992;19:499-507.
26. 26. Omvik P, Herland OB, Thaulow E, et al. Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension. J Hum Hypertens. 1995;9(Suppl 1):S17-S24.
27. 27. Walle PO, Westergren G, Dimenas E, et al. Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being. J Clin Pharmacol. 1994;34:742-747.
28. 28. Anderson RT, Hogan P, Appel L, et al. Baseline correlates with quality of life among men and women with medication-controlled hypertension: The trial of nonpharmacologic interventions in the elderly (TONE). J Am Geriatr Soc. 1997;45:1080-1085.
29. 29. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314: 1657-1664.
30. 30. Croog SH, Kong BW, Levine S, et al. Hypertensive black men and women: Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group. Arch Intern Med. 1990;150:1733-1741.
31. 31. Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens. 1994;7:329-339.
32. 32. Jenkins CD, Stanton BA, Niemeryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988;41:313-321.
33. 33. Testa MA, Hollenberg NK, Andersen RB, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. Am J Hypertens. 1991;4:363-373.
34. 34. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: The TAIM Study. Ann Intern Med. 1991;114:613-620.
35. 35. Wassertheil-Smoller S, Oberman A, Blaufox MD, et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study: Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens. 1992;5:37-44.
36. 36. Fletcher AH, Chester PC, Hawkins CM, et al. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertens. 1989;3:125-130.
37. 37. Fletcher AE, Bulpitt CJ, Hawkins CM, et al. Quality of life on antihypertensive therapy: A randomized double-blind controlled trial of captopril and atenolol. J Hypertens. 1990;8:463-466.
38. 38. Kellner R, Sheffield BF. A self-rating scale of distress. Psychol Med. 1973;3:88-100.
39. 39. Palmer A, Fletcher A, Hamilton G, et al. A comparison of verapamil and nifedipine on quality of life. Br J Clin Pharmacol. 1990:30:365-370.
40. 40. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118:622-629.
41. 41. Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality-of-life and health status instruments: Development of scientific review criteria. Clin Ther. 1996;18:979-992.
42. 42. Fletcher AE, Beevers DC, Dollery CT, et al. The effects of two centrally-acting antihypertensive drugs on the quality of life. Eur J Clin Pharmacol. 1991;41:397-400.
43. 43. Palmer AJ, Fletcher AE, Rudge PJ, et al. Quality of life in hypertensives treated with atenolol or captopril: A double-blind crossover trial. J Hypertens. 1992;10: 1409-1416.
44. 44. Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: A practical approach. Br J Clin Pharmacol. 1990:30:353-364.
45. 45. Himmelberger DU, Budd DW, Nelsen L, Markson LE. Reducing the number of questions in a QOL questionnaire: How to select good questions. Drug Inf J. 1997; 31:1419. Abstract.
46. 46. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. Oxford, England: Oxford University Press; 1989.
47. 47. Snedecor GW, Cochran WG. Statistical Methods. 6th ed. Ames, Iowa: The Iowa State University Press; 1967.
48. 48. Weir MR, Prisant LM, Papademetriou V, et al. Antihypertensive therapy and quality of life: Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Am J Hypertens. 1996; 9:854-859.
49. 49. Fazio AF. A concurrent validational study of the NCHS General Well-Being schedule. Vital Health Stat. 1977;2:1-53.